Compare Eaton Corporation plc (ETN) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs Novartis AG — how do they compare? Eaton Corporation plc trades at $428.7 (market cap $164.88B), while Novartis AG trades at $142.86 (market cap $268.57B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Eaton Corporation plc for 31 Days and Novartis AG for 82 Days on average.
| ETN | NVS | |
|---|---|---|
Market Cap | $164.88B | $268.57B |
Volume | 2,535,086 | 1,532,573 |
Sector | Industrials | Health |
52-Week High | $459.96 | $168.62 |
52-Week Low | $315.82 | $121.80 |
Typical Hold Time | 31 Days | 82 Days |
Enterprise Value | $185.51B | $309.89B |
Dividend Yield | 1.04% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $431.33, down 3.09% today but maintains strong analyst support with 70% buy ratings. The company shows consistent earnings beats and robust profitability with 12.75% net margins. Technical indicators suggest a bullish trend with support at $426 and resistance at $434. Recent acquisitions in data center and utility markets position ETN for durable growth in key infrastructure sectors.
Outlook remains positive with a $502.38 consensus price target representing 16% upside. Key opportunities include data center demand and grid modernization, while risks involve execution of recent acquisitions and potential market volatility. The company's strong backlog and strategic positioning in high-growth infrastructure markets support continued investor confidence.
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
